Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors and endocrine therapy are the gold standards for systemic therapy for patients with hormone-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer. Following progression, no prospective randomized data exi...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Ioana-Miruna Stanciu, Cristina Florina Pirlog, Andrei-Wilhelm Anghel, Andreea Ioana Parosanu, Cristina Mihaela Olaru, Cristina Orlov-Slavu, Ion Cristian Iaciu, Ana Maria Popa, Radu Constantin Vrabie, Cornelia Nitipir
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2023-04-01
Serie:	Medicina
Soggetti:	CDK4/6 inhibitors CDK4/6 rechallenge CDK4/6 toxicity ribociclib abemaciclib
Accesso online:	https://www.mdpi.com/1648-9144/59/4/696
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!